Trial Profile

Phase 1/2 PoC trial assessing VB517 in healthy volunteers as well as chronic urticaria patients

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 30 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VB 517 (Primary)
Indications Chronic urticaria; Mastocytosis
Focus Adverse reactions; Proof of concept; Therapeutic Use

Most Recent Events

21 May 2025 According to a Alumis media release, Alumis Inc. merged with ACELYRIN, Inc. and subsequently changed its name to Alumis Inc.
14 Aug 2023 According to an ACELYRIN media release, the company expects to announce top-line results in the second half of 2024.
15 Jun 2023 Status changed from planning to recruiting as per ACELYRIN media release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com